These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22078648

  • 1. Spanish consensus on the use of natalizumab (Tysabri(®))--2011.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Arbizu T, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Montalbán X.
    Neurologia; 2012 Sep; 27(7):432-41. PubMed ID: 22078648
    [Abstract] [Full Text] [Related]

  • 2. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X.
    Neurologia; 2015 Jun; 30(5):302-14. PubMed ID: 24360652
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. [Natalizumab (Tysabri) prescription practices of neurologists in southern France].
    Rocher F, Cohen M, Lebrun C.
    Rev Neurol (Paris); 2010 Apr 17; 166(4):412-8. PubMed ID: 19846185
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 17; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 17; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Aug 17; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 8. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 17; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D, Giovannoni G.
    Pract Neurol; 2012 Feb 17; 12(1):25-35. PubMed ID: 22258169
    [Abstract] [Full Text] [Related]

  • 10. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 11. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Dec 15; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 12. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 13. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 01; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 01; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 15. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 16. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug 30; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

  • 17. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun 29; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 20. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 29; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.